Search
CytomX Therapeutics Inc
CTMXAdd to Watchlist
2.950USD
0.0000.00%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
502.05MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of CytomX Therapeutics Inc is 9.00, ranking 16 out of 389 in the Biotechnology & Medical Research industry. The average price target is 6.50, with a high of 10.00 and a low of 6.00.
Analyst Rating
Based on
8
analysts
Strong Buy
Current Rating
12.571
Target Price
+313.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
CytomX Therapeutics Inc
CTMX
8
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is CytomX Therapeutics Inc's expected revenue for the next quarter?
CytomX Therapeutics Inc's expected revenue is 12.31M.
What is CytomX Therapeutics Inc's price target?
Analysts forecast that CytomX Therapeutics Inc's price target is USD 6.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 6.00.
How have CytomX Therapeutics IncCTMX's recent earnings per share performed?
The market expectation was USD -0.10, while CytomX Therapeutics IncCTMX's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.08.
What is the analyst rating for CytomX Therapeutics Inc?
Based on the ratings of CytomX Therapeutics Inc's stock from 8 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
